Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis
S Qin, Z Xv, X Chen, S Wang, H Lu, J Li, X Guo… - Frontiers in …, 2023 - frontiersin.org
Background This Bayesian network meta-regression analysis provides a head-to-head
comparison of first-line therapeutic immune checkpoint inhibitors (ICI) and tyrosine kinase …
comparison of first-line therapeutic immune checkpoint inhibitors (ICI) and tyrosine kinase …
[HTML][HTML] Sco** review of economic analyses of rare kidney diseases
Introduction Rare kidney diseases (RKD) place a substantial economic burden on patients
and health systems, the extent of which is unknown and may be systematically …
and health systems, the extent of which is unknown and may be systematically …
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a …
N Dhanji, TC Decimoni, MTD Dyer, JR May… - Journal of Medical …, 2023 - Taylor & Francis
Objective Nivolumab plus ipilimumab (NIVO+ IPI) and pembrolizumab plus axitinib (PEM+
AXI) have demonstrated significant clinical benefits as first-line (1 L) treatments for …
AXI) have demonstrated significant clinical benefits as first-line (1 L) treatments for …
Immunotherapy-based first-line treatment of intermediate-and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from …
AP Oliveira, C Roubik, M Dyer, L Neusquen… - Jornal Brasileiro de …, 2021 - jbes.com.br
Objetivo: Analisar ao longo do tempo o número necessário a tratar (NNT) eo custo para
prevenir um evento (COPE) para nivolumabe+ ipilimumabe (NIVO+ IPI) e pembrolizumabe+ …
prevenir um evento (COPE) para nivolumabe+ ipilimumabe (NIVO+ IPI) e pembrolizumabe+ …
Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer
L Paladini, CRP da Veiga, E Cerqueira… - Journal of Medical …, 2021 - Taylor & Francis
Aims Considering that healthcare systems' financial resources are limited, we aimed to
analyze the number needed to treat (NNT) and cost of preventing an event (COPE) related …
analyze the number needed to treat (NNT) and cost of preventing an event (COPE) related …
Comment on: Immunotherapy-based first-line treatment of intermediate-and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing …
LP Leonart, B Riveros, F Berlinski… - Jornal Brasileiro de …, 2022 - jbes.com.br
Comment on: Immunotherapy-based first- line treatment of intermediate- and poor- risk
advanced renal cell carcinoma: number need Page 1 267 J Bras Econ Saúde 2022;14(3):267-8 …
advanced renal cell carcinoma: number need Page 1 267 J Bras Econ Saúde 2022;14(3):267-8 …
Immunotherapy-based first-line treatment of intermediate-and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from …
AP Casagrande Drozda Oliveira… - … Brazilian Journal of …, 2021 - search.ebscohost.com
Objective: To perform an analysis over time of the number needed to treat (NNT) and the
cost of preventing an event (COPE) for nivolumab+ ipilimumab (NIVO+ IPI) and …
cost of preventing an event (COPE) for nivolumab+ ipilimumab (NIVO+ IPI) and …